Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5994127

Title:In vivo production and delivery of erythropoietin or insulinotropin for gene therapy
Inventors:Selden, Richard F; Wellesley, MA, USA
Treco, Douglas; Arlington, MA, USA
Heartlein, Michael W.; Boxborough, MA, USA
Summary:This invention describes a novel erythropoietin delivery composition by which primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, are transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1(GLP-1)]. Such methods by which primary and secondary cells are accordingly transfected include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains which express eruthropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells. Further disclosed are properties of primary and secondary somatic cells, such as fibroblasts, keratinocytes, epithelial cells, endothelial cells, glial cells, neural cells, formed elements of the blood, muscle cells, and other somatic cells. Methods are also provided for culturing such somatic cell precursors, which have been transfected with exogenous DNA encoding EPO or an insulinotropin, which is stably integrated into their genomes or is expressed in the cells episomally. Such methods may be used in gene therapy for expressing exogenous DNA and also for the development of therapeutic products.
Abstract:The present invention relates to transfected primary and secondary somatic cells of vertebrate origin, particularly mammalian origin, transfected with exogenous genetic material (DNA) which encodes erythropoietin or an insulinotropin [e.g., derivatives of glucagon-like peptide 1(GLP-1)], methods by which primary and secondary cells are transfected to include exogenous genetic material encoding erythropoietin or an insulinotropin, methods of producing clonal cell strains or heterogenous cell strains which express eruthropoietin or an insulinotropin, methods of gene therapy in which the transfected primary or secondary cells are used, and methods of producing antibodies using the transfected primary or secondary cells. The present invention includes primary and secondary somatic cells, such as fibroblasts, keratinocytes, epithelial cells, endothelial cells, glial cells, neural cells, formed elements of the blood, muscle cells, other somatic cells which can be cultured and somatic cell precursors, which have been transfected with exogenous DNA encoding EPO or an insulinotropin, which is stably integrated into their genomes or is expressed in the cells episomally.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5994127
Application Number:US1994000334455
Date Filed:04/11/1994
Date Published:30/11/1999
Assignee:Transkaryotic Therapies, Inc., Cambridge, MA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/13/2021